MedPath
Found 43 clinical trials|View Analysis
Sort by:

Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs

Not Applicable
Not yet recruiting
Conditions
NSCLC
Chemotherapy
Leptomeningeal Metastases
EGFR-TKI
AK112
Interventions
First Posted Date
2025-01-09
Last Posted Date
2025-01-09
Lead Sponsor
Jiangsu Province Nanjing Brain Hospital
Target Recruit Count
36
Registration Number
NCT06766591

Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study

Phase 2
Recruiting
Conditions
Non-small Cell Lung Cancer (NSCLC)
EGFR Mutation-Positive Lung Cancer
Brain Metastases
Leptomeningeal Metastases
Intracranial Tumor Progression
Interventions
Drug: The treatment regimen is Furmonertinib combined with Bevacizumab.
First Posted Date
2024-12-11
Last Posted Date
2024-12-11
Lead Sponsor
Li-kun Chen
Target Recruit Count
70
Registration Number
NCT06728865
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guang zhou, Guang dong, China

Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC

Phase 1
Recruiting
Conditions
Lung Cancer (NSCLC)
Leptomeningeal Metastasis
Interventions
First Posted Date
2024-10-29
Last Posted Date
2024-10-29
Lead Sponsor
Shanghai Chest Hospital
Target Recruit Count
19
Registration Number
NCT06663306
Locations
🇨🇳

Shanghai Chest Hospital, Shanghai, China

Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases

Phase 2
Not yet recruiting
Conditions
Non-small Cell Lung Cancer
Interventions
Drug: Intrathecal Pemetrexed and high-dose Furmonertinib plus bevacizumab
First Posted Date
2024-08-05
Last Posted Date
2024-08-06
Lead Sponsor
Hunan Province Tumor Hospital
Target Recruit Count
30
Registration Number
NCT06537297
Locations
🇨🇳

Hunan Cancer Hospital, Changsha, Hunan, China

Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer

Phase 2
Recruiting
Conditions
Metastatic Malignant Neoplasm in the Leptomeninges
Metastatic Breast Carcinoma
Stage IV Lung Cancer AJCC v8
Metastatic Lung Non-Small Cell Carcinoma
Anatomic Stage IV Breast Cancer AJCC v8
Interventions
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Other: Electronic Health Record Review
Procedure: Lumbar Puncture
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Radiation: Proton Beam Craniospinal Irradiation
Other: Survey Administration
Radiation: Volume Modulated Arc Therapy
First Posted Date
2024-07-24
Last Posted Date
2025-01-10
Lead Sponsor
University of Washington
Target Recruit Count
22
Registration Number
NCT06518057
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer

Phase 1
Not yet recruiting
Conditions
Leptomeningeal Metastases
Interventions
First Posted Date
2024-06-17
Last Posted Date
2024-06-18
Lead Sponsor
Guangzhou Medical University
Target Recruit Count
34
Registration Number
NCT06462092

Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases

Phase 2
Recruiting
Conditions
Non-Small Cell Lung Cancer
Interventions
First Posted Date
2024-06-04
Last Posted Date
2024-06-04
Lead Sponsor
Hunan Province Tumor Hospital
Target Recruit Count
220
Registration Number
NCT06440954
Locations
🇨🇳

Hunan Cancer Hospital, Changsha, Hunan, China

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

Phase 4
Not yet recruiting
Conditions
Carcinoma, Non-Small-Cell Lung
Brain Metastases
Leptomeningeal Metastasis
Interventions
First Posted Date
2024-02-28
Last Posted Date
2024-02-28
Lead Sponsor
Guangdong Association of Clinical Trials
Target Recruit Count
50
Registration Number
NCT06282874
Locations
🇨🇳

Guangdong Provincial Perople's Hospital, Guangzhou, Other (Non U.s.), China

Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC

Phase 2
Not yet recruiting
Conditions
NSCLC Associated With Leptomeningeal Metastases
Interventions
Drug: Tislelizumab, pemetrexed
First Posted Date
2023-11-15
Last Posted Date
2023-11-24
Lead Sponsor
West China Hospital
Target Recruit Count
17
Registration Number
NCT06132698

Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC

Phase 2
Conditions
Non Small Cell Lung Cancer
Interventions
First Posted Date
2023-04-14
Last Posted Date
2023-04-14
Lead Sponsor
First Affiliated Hospital of Zhejiang University
Target Recruit Count
30
Registration Number
NCT05813522
Locations
🇨🇳

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath